HER2 in Brain Metastases: Issues of Concordance, Survival, and Treatment
- 1 October 2002
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 20 (19), 4130-4133
- https://doi.org/10.1200/jco.2002.04.016
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Meningeal Carcinomatosis From Breast Carcinoma Responsive to TrastuzumabJournal of Clinical Oncology, 2001
- Loss of ErbB2 Expression in Pulmonary Metastatic Lesions in OsteosarcomaOncology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- c-erbB-2 protein expression and clinicopathologic features in colorectal cancer.Oncology Reports, 2000
- Trastuzumab in CSFJournal of Clinical Oncology, 2000
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancerInternational Journal of Cancer, 1991